Diffuse large B cell lymphoma
Conditions
Interventions
Patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who received first-line treatment with vilpotuzumab:None
Sponsors
Fifth Affiliated Hospital, Sun Yat-Sen University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Pathologically confirmed diagnosis of DLBCL; 2.No concurrent diagnosis of other malignancies; 3.Absence of other severe comorbidities that may significantly affect efficacy evaluation, lead to treatment discontinuation, or result in death; 4.Patients have provided written informed consent for the use of their residual (to-be-discarded) pathological biopsy samples for clinical research, and the relevant pathological samples are stored in the hospital’s Department of Pathology;
Exclusion criteria
Exclusion criteria: 1.Did not receive a polatuzumab vedotin-containing regimen from the first cycle of first-line therapy; 2.Missing data rate for key clinical indicators exceeding 10%; 3.Did not complete the planned first-line therapy and undergo post-treatment efficacy evaluation;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete Response Rate (CRR);Progression-Free Survival (PFS);Safety Outcomes (including: leukopenia, neutropenia, thrombocytopenia, hemoglobin reduction, infection, hepatic dysfunction, hematuria, chronic kidney injury, arrhythmia, heart failure, allergic reaction, nausea and vomiting, constipation, diarrhea, abdominal pain, oral ulceration, peripheral neuropathy); | — |
Countries
China
Contacts
Public ContactChen Nan
Fifth Affiliated Hospital, Sun Yat-Sen University
Outcome results
None listed